Sobiovir indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
Dosage and Administration:
The recommended dose of Sofosbuvir is one 400 mg tablet, taken orally, once daily with or without food.
Monotherapy of Sofosbuvir is not recommended for treatment of CHC.
It is not known whether Sofosbuvir and its metabolites are present in human breast milk. The predominant circulating metabolite was the primary component observed in the milk of lactating rats, without effect on nursing pups. Because of the potential for adverse reactions from the drug in nursing infants, a decision must be made whether to discontinue nursing or discontinue treatment with ribavirin-containing regimens, taking into account the importance of the therapy to the mother. See also the prescribing information for ribavirin.
Before taking Sofosbuvir, tell your healthcare provider if you:
•have liver problems other than hepatitis C infection
•have had a liver transplant
•have severe kidney problems or you are on dialysis
•have any other medical condition
•are breastfeeding or plan to breastfeed. It is not known if Sofosbuvir passes into your breast milk. You and your healthcare provider should decide if you will take Sofosbuvir or breastfeed. You should not do both.
Do not stop taking Sofosbuvir without first talking with your healthcare provider
If you miss a dose of Sofosbuvir, take the missed dose as soon as you Remember the same day. Do not take more than 1 tablet (400 mg) of Sofosbuvir in a day Take Your next dose of Sofosbuvir at your regular time the next day.